FDA grants accelerated approval to BeOne Medicines’ next-generation BCL2 inhibitor

BeOne Medicines (NASDAQ:ONC) announced that Beqalzi is now authorized for MCL patients who have previously been treated with a Bruton’s tyrosine kinase (BTK) inhibitor.

The accelerated approval is based on early clinical data demonstrating the drug's efficacy in a difficult-to-treat population where options are traditionally limited following BTK failure.

Sonrotoclax was engineered as a foundational, next-generation BCL2 inhibitor.

According to the company, the molecule was designed to offer greater potency and selectivity than the first-generation inhibitors currently on the market.

By refining the pharmacologic profile, BeOne aims to provide a treatment that balances improved efficacy with a more favorable tolerability and convenience profile for patients managing chronic lymphatic malignancies.

As part of the accelerated approval pathway, continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

BeOne Medicines, which maintains triple listings on the Nasdaq, HKEX, and SSE, plans to integrate Beqalzi into its broader global oncology portfolio as it pursues additional indications for the molecule.